<DOC>
	<DOCNO>NCT01910155</DOCNO>
	<brief_summary>The objective study compare relative efficacy safety test formulation ciprofloxacin 0.3 % /dexamethasone 0.1 % sterile otic suspension ( Par Pharmaceutical Companies , Inc. ) already-marketed formulation CIPRODEXÂ® ( ciprofloxacin 0.3 % /dexamethasone 0.1 % ) sterile otic suspension ( Alcon ) treatment acute bacterial otitis externa .</brief_summary>
	<brief_title>A Bioequivalence Study Two Ciprofloxacin/Dexamethasone Formulations Patients With Otitis Externa</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Externa</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Male nonpregnant , non lactating female 1865 year age inclusive . 2 . Signed informed consent form , meet criteria current FDA regulation . 3 . If female child bear potential , negative urine pregnancy test baseline visit prepare abstain sexual intercourse use reliable method contraception study ( e.g. , condom , IUD , oral , injected , transdermal implant hormonal contraceptive ) . Patients hormonal contraceptive must method/type least 28 day prior start study remain throughout study . 4 . The presence infection confirm positive bacterial culture presence Pseudomonas aeruginosa Staphylococcus aureus . As result bacterial culture immediately know , patient meet inclusion/exclusion criterion may enrol study pending result bacterial culture . 5 . Clinical sign symptom consistent bacterial otitis externa define combined Total Symptom Score ( TSS ) least 6 score least 2 otalgia use follow scale 0=none , 1=mild , 2=moderate , 3=severe . 1 . Females pregnant , breast feeding , anticipate become pregnant study . 2 . Signs symptom otitis externa longer 21 day prior screen inclusion study . 3 . Previous episode otitis externa within previous 6 month 2 episode within previous 12 month . 4 . Been provide therapeutic drug treatment current episode otitis externa . 5 . Known history , ear exam reveals tympanic membrane perforation damage reason . 6 . Current previous history otologic surgery include insertion/removal tympanostomy tube infect ear ( ) . 7 . Clinical diagnosis suggest current sign symptom cause acute bacterial otitis externa e.g . chronic suppurative otitis externa , acute otitis medium 8 . Clinical diagnosis malignant otitis externa 9 . Mastoid cavity , stenosis , exostosis tumor either ear noninfectious disease either ear . 10 . Suspected concurrent fungal viral infection ( e.g . herpes simplex ) either ear . 11 . Dermatitis infect ear psoriasis seborrhea would complicate evaluation . 12 . Significant underlying disease diabetes , HIV immunocompromised condition receive therapy may cause patient immunocompromised . 13 . Significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participation could jeopardize integrity study evaluation . 14 . Investigator believe severity infection systemic antibiotic would prefer treatment option . 15 . Use systemic antibacterial product topical antibacterial product ear ( ) within 28 day screen study . 16 . Use systemic antiinflammatory product topical antiinflammatory product ear ( ) ( corticosteroids NSAIDs ) within 7 day screen study . 17 . Use topical otic medication affect ear within 2 week prior screen . 18 . Use astringent vinegar , alcohol medicate cleanse swab ear within 48 hour baseline bacterial culture swab . 19 . Any known hypersensitivity ciprofloxacin carboxyquinolone derivative , dexamethasone corticosteroid ingredient formulation . 20 . Receipt drug device part research study within 30 day prior dose . 21 . Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>